Collectively these results suggest that SPINK1 silencing (potentially involving MTs overexpression) confers sensitivity to doxorubicin in colon cancer cells, which strengthen the rationale for using the combinatorial treatment approach for the SPINK1+ CRC patients. The gene discussed is SPINK1; the disease is colonic neoplasm.